News | Nuclear Imaging | June 10, 2017

GE Healthcare SPECT/CT and PET/CT Systems Enhance Personalized Patient Care

Company features high-quality molecular imaging of Discovery MI and Discovery NM/CT 670 CZT at SNMMI, along with upgrade kits for both

GE Healthcare SPECT/CT and PET/CT Systems Enhance Personalized Patient Care

June 10, 2017 — GE Healthcare showcased positron emission tomography (PET) and single photon emission computed tomography/computed tomography (SPECT/CT) advancements at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2017 that will enable clinicians to deliver personalized, quantitative results to patients. Introduced in 2016, Discovery MI and Discovery NM/CT 670 CZT both offer flexible, digital capabilities that help clinicians guide treatment and support patients with sensitive care while creating an environment for compelling research.

Discovery NM/CT 670 CZT features a state-of-the-art digital detector that represents the next generation of SPECT/CT systems. Powered by the quantitative applications available on GE Healthcare’s nuclear medicine-dedicated workstation, Xeleris 4.0, clinicians can enjoy the certainty of quantitation in customizable, easy-to-read reports across multiple care areas.

According to the company, Discovery NM/CT 670 CZT remains the world’s only general-purpose SPECT/CT imaging system with cadmium zinc telluride (CZT) technology, which enables direct conversion of photons into a digital signal, thus making it more efficient. Over the last year, research collaborations with Rambam Health Center, Barnes-Jewish Hospital, St. Jean Clinic and Hospices Civils de Lyon have demonstrated Discovery NM/CT 670 CZT’s potential impact in guiding patient management, dose reduction and department operations. The system was engineered for patient comfort and to deliver greater than 40 percent improvements in SPECT contrast to noise ratio2, as well as up to a 75 percent dose or time reduction.1

Having the ability to complete multiple scans in a single visit and reduce the injected dose or the scan time represents not only an improved patient experience, but also provides economic and clinical benefits. “The system provides further dose reduction over conventional technologies, and therefore, it could lower the overall cost of radiopharmaceuticals and deliver financial benefits to the nuclear medicine department,” stated Prof. C. Scheiber, Hospices Civils de Lyon, France.

GE Healthcare also introduced Discovery 670 DR, a digital-ready conventional SPECT/CT system, requiring a simple two-day in-field upgrade to CZT technology. The system’s modular design offers an investment protection for easy upgradability to digital. Both Discovery NM/CT 670 CZT and Discovery 670 DR are now powered by the latest 16 slice CT sub-system, offering additional improvements in CT image quality with an overlap reconstruction which enables 32 slices per rotation.

Discovery MI was created to help clinicians diagnose and stage disease earlier and better guide treatment strategies while enabling more compelling research with more novel, faster decaying tracers. Discovery MI brings together the sensitivity of digital detection, with innovative reconstruction technology: the combination of Time-of-Flight (TOF) and Q.Clear. The result is outstanding resolution to improve the detection of small lesions.

“One of the most striking features of Discovery MI is the improved sensitivity,” said Ronny Ralf Buechel, M.D., a cardiologist and nuclear medicine physician from Zurich. “We didn’t know how low we could go with the injected activity and radiation dose, so we began to cautiously lower the dose. Now, we are around 50 percent of the injected dose for PET scans compared to the prior system — around 1 mSv for a complete rest/stress study and what remains important for cardiac imagers is the reduced activity of ammonia without any deterioration in image quality.”

GE plans to introduce a scalable offering to the Discovery MI that will make a three-ring, 15cm axial field of view available, which provides greater access to digital technology to more customers. The three-ring is fully upgradeable in existing units in the field to the 20cm four-ring. With this flexibility, this system is a long-term, fully scalable investment that will allow hospitals to upgrade as patient and department needs change over the years.

GE Healthcare is also introducing Discovery MI DR, a versatile, digital-ready PET/CT system that provides reliable images, faster scan times, low dose and accurate quantitation and allows physicians to image clinically challenging cases, including cardiac and brain imaging. Discovery MI DR’s modular design allows customers to acquire the system that fits their needs and allows for easy and cost-effective upgrade options.

For more information: www.gehealthcare.com

References

1. Together with Clarity 2D/Evolution Technology. Compared to D670 Pro/ES/DR without Clarity 2D/Evolution Technology. Demonstrated in phantom testing using the NEMA IEC Body Phantom.

2. Demonstrated in phantom testing using the NEMA IEC Body Phantom at 50 percent scan times with Evolution Technology.

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.
Huntsman Cancer Institute Installs First Preclinical nanoScan 3T PET/MRI in U.S.
News | PET-MRI | October 10, 2018
The Center for Quantitative Cancer Imaging at Huntsman Cancer Institute (HCI) at the University of Utah in Salt Lake...